Halozyme Therapeutics (HALO) – Investment Analysts’ Recent Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Halozyme Therapeutics (NASDAQ: HALO) in the last few weeks:

• 10/16/2026 – Halozyme Therapeutics was given a new $130.00 price target by Stifel Nicolaus.
• 10/13/2026 – Halozyme Therapeutics was upgraded by Zacks Research from “hold” to “strong-buy”.
• 10/13/2026 – Halozyme Therapeutics had its price target raised by TD Cowen from $105.00 to $130.00. They now have a “buy” rating on the stock.
• 10/8/2026 – Halozyme Therapeutics had its price target raised by JPMorgan Chase & Co. from $70.00 to $78.00. They now have a “neutral” rating on the stock.
• 10/7/2026 – Halozyme Therapeutics had its price target raised by HC Wainwright from $115.00 to $130.00. They now have a “buy” rating on the stock.
• 9/2/2026 – Halozyme Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $115.00 price target on the stock.
• 8/31/2026 – Halozyme Therapeutics was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction on Thursday, October 8th. The shares were sold at an average price of $109.40, for a total value of $2,188,000.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at $83,995,132. The trade was a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the transaction, the director owned 40,418 shares in the company, valued at approximately $4,154,970.40. This represents a 3.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 125,852 shares of company stock valued at $13,538,046 in the last quarter. 2.50% of the stock is currently owned by insiders.

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.